http://rdf.ncbi.nlm.nih.gov/pubchem/patent/SG-10201914127P-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5a185d83dfbd190565db69a54665688e
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D455-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14
filingDate 2017-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e4066fc0d7b634f5a1687027eea718ed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf76e311c32112425f5dd2991ebe2f86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b465b4f187e0ddf7896cd1e1222ebf84
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d23b7cbf746968841a0ed569f2093104
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ae57ce08bc6d63f88264eb152cd2543
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90e83ce72ba8fe6e9e1e77fa2d9a055d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e5509f4a13f6ca2bc31b0fbdfc14a8e3
publicationDate 2020-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber SG-10201914127P-A
titleOfInvention Isoquinolin-3-yl carboxamides and preparation and use thereof
abstract ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A. (NO SUITABLE FIGURE)
priorityDate 2016-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID14925627
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID32771
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID1859
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID487755
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID458545
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID395233
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID25255
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID532989
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID13548
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID446302
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID421969719

Total number of triples: 40.